 The recent emergence of novel influenza virus strains in human populations has encouraged efforts to develop vaccines for a potential pandemic. The objectives of this study are to evaluate the safety of intramuscular IM subvirion inactivated H5N1 vaccine in healthy children aged 2 through 10 years and to determine the immunogenicity profile of IM subvirion inactivated H5N1 vaccine in healthy children approximately 1 month following receipt of the second of 2 doses of vaccine. Study endpoints include: adverse event AE and serious adverse event SAE information solicited in-clinic and via memory aids, concomitant medications, and periodic targeted physical assessments, as indicated; proportion of subjects achieving a serum hemagglutination inhibition antibody titer of 1:40 against the influenza AH5N1 virus 28 days after receipt of second dose of vaccine approximately Day 56; geometric mean titer and the frequency of 4-fold or greater increases in hemagglutination inhibition antibody titers 28 days after receipt of second dose of vaccine approximately Day 56; and development of serum antibody responses against antigenically drifted variants of influenza H5N1 virus. This study is linked to DMID protocol 06-0072. Up to 55 healthy children, aged 2 through 10 years, who previously participated in DMID 04-077, will be eligible for enrollment in this multimember, open-label, phase III clinical trial to receive at least 2 and up to 3 doses of an inactivated influenza AH5N1 vaccine at a 45-micrograms dose. The vaccine dosage level that will be used in this study was chosen based upon safety and immunogenicity data collected previously in adults and children. The injection volume of the 90-micrograms dose is 1 mL for the vaccine being used in this study, but this is considered unacceptable in this age group. Therefore, the 45-micrograms dose 0.5 ml volume has been selected. Twenty three subjects who were previously enrolled and assigned to placebo in the DMID 04-077 study A Randomized, Double-Blinded, Placebo-Controlled, Phase III, Study of the Safety, Reactogenicity, and Immunogenicity of Intramuscular Inactivated Influenza AH5N1 Vaccine in Healthy Children Aged 2 Years Through 9 Years along with up to 32 subjects from a single site who were incompletely immunized are eligible for enrollment in this study. Vaccine will be administered into the deltoid or if age appropriate thigh muscle. All subjects will receive 2 doses of the vaccine approximately 28 days apart. At month 6, subjects parents or guardians will be called to assess the subjects for serious adverse events. Blood collection for immunogenicity studies will be at the discretion of the parents or legal guardians. Should data evaluating a third dose of the influenza AH5N1 vaccine show enhanced immunogenicity in pediatric subjects participating in DMID 04-077, parentsguardians of subjects who received vaccine will be offered the possibility of a third dose for their participating children. 